GlassScriptPhysician profile
William Brandon Winfrey
NPI 1871081992
$1,009.41
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.63 · 2022: $996.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $291.58 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $145.50 | 2022 | |
| United Therapeutics Corporation | $131.91 | 2022 | |
| Novartis Pharmaceuticals Corporation | $90.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $74.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $67.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.92 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.57 | 2022 | |
| Alnylam Pharmaceuticals INC. | $35.78 | 2022 | |
| Merck Sharp & Dohme LLC | $15.94 | 2022 | |
| Irhythm Technologies, INC. | $15.33 | 2022 | |
| Amgen INC. | $15.13 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.63 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Winfrey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.